iBio, Inc. provided revenue guidance for the first half, second half and full year of fiscal 2022. For the first half, the company expects a sequential decline in revenue compared to the second half of fiscal 2021. For the second half, the company expects higher growth in revenue. For the full year, the company expects, irrespective of quarterly fluctuations, continued year-on-year revenue growth.